Foley & Lardner LLP Partner Kyle Faget is quoted in the Pharmaceutical Technology article, “What a mild recession could mean for small biotechs in 2023,” offering guidance for smaller- and medium-sized biotech companies amid economic uncertainty.
Though larger, more established pharmaceutical companies may have the infrastructure and financial cushion to fall back on, Faget said, “It’s going to be a harder environment for smaller and medium biotechs. Getting funding is going to be more difficult.”
“Everybody has to focus in more and probably take a more conservative approach and take deeper diligence. In a more robust economy, you might be able to take some research risks that might be too expensive to do in the coming year,” she explained.
People
Related News
03 May 2024
In the News
Jeff Symons’ Move to Foley Featured in Press
Foley & Lardner LLP partner Jeff Symons is featured in legal press for his recent arrival to the firm
03 May 2024
In the News
Nathaniel Lacktman on Healthleaders Podcast– ‘We’re seeing maturity in the telemedicine market’
Foley & Lardner LLP partner Nathaniel Lacktman discussed the upcoming American Telemedicine Association’s annual conference, new developments in telemedicine and digital health, the regulatory context, and the prospects for the industry’s future
02 May 2024
In the News
Jennifer Hennessy on American Privacy Rights Act – ‘This law does have teeth’
Foley & Lardner LLP partner Jennifer Hennessy assesses the prospects of what could be the first federal data privacy law passed in the United States